Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells.

PMID: 32110891
Journal: Journal of Clinical Medicine
Year: 2020
Reference: J Clin Med. 2020 Feb 26;9(3). pii: jcm9030625. doi: 10.3390/jcm9030625.
Impact factor:
Publication type: Paper in international publication
Authors: Alcina, Antonio; Bosch, Elena; Castillo-Trivino, Tamara; Comabella, Manuel; Eixarch, Herena; Fedetz, Maria; Fernandez, Oscar; Gil-Varea, Elia; Izquierdo, Guillermo; Leyva, Laura et al.
DOI: 10.3390/jcm9030625

A new standard of care for patients with high-risk rhabdomyosarcoma? - Authors' reply.

PMID: 31908304
Journal: LANCET ONCOLOGY
Year: 2020
Reference: Lancet Oncol. 2020 Jan;21(1):e3. doi: 10.1016/S1470-2045(19)30812-5.
Impact factor: 33.752
Publication type: Letter or abstract
Authors: Bisogno, Gianni, Ferrari, Andrea, Melcon, Soledad Gallego, De Salvo, Gian Luca, Bergeron, Christophe, Jenney, Meriel et al.
DOI: 10.1016/S1470-2045(19)30812-5

A new standard of care for patients with high-risk rhabdomyosarcoma? - Authors' reply.

PMID: 31908304
Journal: LANCET ONCOLOGY
Year: 2020
Reference: Lancet Oncol. 2020 Jan;21(1):e3. doi: 10.1016/S1470-2045(19)30812-5.
Impact factor:
Publication type: Letter or abstract
Authors: Bergeron, Christophe; Bisogno, Gianni; De Salvo, Gian Luca; Ferrari, Andrea; Jenney, Meriel; Melcon, Soledad Gallego et al.
DOI: 10.1016/S1470-2045(19)30812-5

A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer.

PMID: 32799562
Journal: Future Oncology
Year: 2020
Reference: Future Oncol. 2020 Nov;16(33):2691-2700. doi: 10.2217/fon-2020-0334. Epub 2020 Aug 17.
Impact factor: 2.66
Publication type: Paper in international publication
Authors: Verdaguer, Helena, Acosta, Daniel, Macarulla, Teresa et al.
DOI: 10.2217/fon-2020-0334

A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer.

PMID: 32799562
Journal: Future Oncology
Year: 2020
Reference: Future Oncol. 2020 Nov;16(33):2691-2700. doi: 10.2217/fon-2020-0334. Epub 2020 Aug 17.
Impact factor:
Publication type: Paper in international publication
Authors: Acosta, Daniel; Macarulla, Teresa; Verdaguer, Helena et al.
DOI: 10.2217/fon-2020-0334

A novel autologous-made matrix using hyaline cartilage chips and platelet-rich growth factors for the treatment of full-thickness cartilage or osteochondral defects: Preliminary results.

PMID: 31835970
Journal: Journal of Orthopaedic Surgery
Year: 2020
Reference: J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(1):2309499019887547. doi: 10.1177/2309499019887547.
Impact factor:
Publication type: Paper in international publication
Authors: Alentorn-Geli, Eduard; Alvarez-Diaz, Pedro; Barastegui, David; Cugat, Ramon; Cusco, Xavier; Garcia-Balletbo, Montserrat; Laiz, Patricia; Navarro, Jordi; Samitier, Gonzalo; Seijas, Roberto et al.
DOI: 10.1177/2309499019887547

A novel clinical risk prediction model for myocardial infarction, coronary revascularization, and cardiac death according to clinical, exercise, and gated SPECT variables (VH-RS).

PMID: 31049558
Journal: European Heart Journal-Cardiovascular Imaging
Year: 2020
Reference: Eur Heart J Cardiovasc Imaging. 2020 Feb 1;21(2):210-221. doi: 10.1093/ehjci/jez078.
Impact factor: 4.841
Publication type: Paper in international publication
Authors: Romero-Farina, Guillermo, Candell-Riera, Jaume, Aguade-Bruix, Santiago, Garcia Dorado, David et al.
DOI: 10.1093/ehjci/jez078

A novel clinical risk prediction model for myocardial infarction, coronary revascularization, and cardiac death according to clinical, exercise, and gated SPECT variables (VH-RS).

PMID: 31049558
Journal: European Heart Journal-Cardiovascular Imaging
Year: 2020
Reference: Eur Heart J Cardiovasc Imaging. 2020 Feb 1;21(2):210-221. doi: 10.1093/ehjci/jez078.
Impact factor:
Publication type: Paper in international publication
Authors: Aguade-Bruix, Santiago; Candell-Riera, Jaume; Garcia Dorado, David; Romero-Farina, Guillermo et al.
DOI: 10.1093/ehjci/jez078

A novel id-iri score: development and internal validation of the multivariable community acquired sepsis clinical risk prediction model.

PMID: 31823148
Journal: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
Year: 2020
Reference: Eur J Clin Microbiol Infect Dis. 2020 Apr;39(4):689-701. doi: 10.1007/s10096-019-03781-y. Epub 2019 Dec 10.
Impact factor: 2.837
Publication type: Paper in international publication
Authors: Diktas, Husrev, Uysal, Serhat, Erdem, Hakan, Cag, Yasemin, Miftode, Egidia, Durmus, Gul, Ulu-Kilic, Aysegul, Alabay, Selma, Szabo, Balint Gergely, Alexandru, Crisan et al.
DOI: 10.1007/s10096-019-03781-y

A novel id-iri score: development and internal validation of the multivariable community acquired sepsis clinical risk prediction model.

PMID: 31823148
Journal: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
Year: 2020
Reference: Eur J Clin Microbiol Infect Dis. 2020 Apr;39(4):689-701. doi: 10.1007/s10096-019-03781-y. Epub 2019 Dec 10.
Impact factor:
Publication type: Paper in international publication
Authors: Al-Majid, Fahad; Alabay, Selma; Alexandru, Crisan; Argemi, Xavier; Arslan-Ozel, Selcan; Atilla, Aynur; Aydin, Emsal; Batirel, Ayse; Bolukcu, Sibel; Cag, Yasemin et al.
DOI: 10.1007/s10096-019-03781-y

A parsimonious score with a free web tool for predicting disability after an ischemic stroke: the Parsifal Score.

PMID: 32458199
Journal: JOURNAL OF NEUROLOGY
Year: 2020
Reference: J Neurol. 2020 May 26. pii: 10.1007/s00415-020-09914-0. doi: 10.1007/s00415-020-09914-0.
Impact factor: 3.956
Publication type: Paper in international publication
Authors: Muino, E, Bustamante, A, Rodriguez-Campello, A, Gallego-Fabrega, C, Ois, A, Carrera, C, Cullell, N, Torres-Aguila, N, Carcel-Marquez, J, Rubiera, M et al.
DOI: 10.1007/s00415-020-09914-0

A parsimonious score with a free web tool for predicting disability after an ischemic stroke: the Parsifal Score.

PMID: 32458199
Journal: JOURNAL OF NEUROLOGY
Year: 2020
Reference: J Neurol. 2020 May 26. pii: 10.1007/s00415-020-09914-0. doi: 10.1007/s00415-020-09914-0.
Impact factor:
Publication type: Paper in international publication
Authors: Bustamante, A; Carcel-Marquez, J; Carrera, C; Cuadrado-Godia, E; Cullell, N; Fernandez-Cadenas, I; Gallego-Fabrega, C; Giralt-Steinhauer, E; Jimenez-Conde, J; Molina, C A et al.
DOI: 10.1007/s00415-020-09914-0

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.

PMID: 32022463
Journal: Cancer Medicine
Year: 2020
Reference: Cancer Med. 2020 Apr;9(7):2317-2329. doi: 10.1002/cam4.2814. Epub 2020 Feb 5.
Impact factor: 3.491
Publication type: Paper in international publication
Authors: Bergua, Juan, Amigo, Maria-Luz, Vall-Llovera, Ferran, Martinez-Sanchez, Pilar, Calbacho, Maria, Garcia-Cadenas, Irene, Garcia-Guinon, Antoni, Sanchez-Sanchez, Maria-Jose, Cervera, Marta, Feliu, Evarist et al.
DOI: 10.1002/cam4.2814

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.

PMID: 32022463
Journal: Cancer Medicine
Year: 2020
Reference: Cancer Med. 2020 Apr;9(7):2317-2329. doi: 10.1002/cam4.2814. Epub 2020 Feb 5.
Impact factor:
Publication type: Paper in international publication
Authors: Amigo, Maria-Luz; Barba, Pere; Bergua, Juan; Calbacho, Maria; Cervera, Marta; Coll, Rosa; Feliu, Evarist; Garcia-Boyero, Raimundo; Garcia-Cadenas, Irene; Garcia-Guinon, Antoni et al.
DOI: 10.1002/cam4.2814

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

PMID: 32781289
Journal: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Year: 2020
Reference: Biol Blood Marrow Transplant. 2020 Nov;26(11):2139-2146. doi: 10.1016/j.bbmt.2020.08.003. Epub 2020 Aug 8.
Impact factor: 3.853
Publication type: Paper in international publication
Authors: Bacher, Ulrike, Nazha, Aziz, Hu, Zhen-Huan, Wang, Tao, Lindsley, R Coleman, Abdel-Azim, Hisham, Aljurf, Mahmoud, Rizzieri, David, Sabloff, Mitchell, Savani, Bipin N et al.
DOI: 10.1016/j.bbmt.2020.08.003

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

PMID: 32781289
Journal: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Year: 2020
Reference: Biol Blood Marrow Transplant. 2020 Nov;26(11):2139-2146. doi: 10.1016/j.bbmt.2020.08.003. Epub 2020 Aug 8.
Impact factor:
Publication type: Paper in international publication
Authors: Abdel-Azim, Hisham; Aljurf, Mahmoud; Alyea, Edwin; Bacher, Ulrike; Bashey, Asad; Cahn, Jean-Yves; Cerny, Jan; Copelan, Edward; DeFilipp, Zachariah; Diaz, Miguel Angel et al.
DOI: 10.1016/j.bbmt.2020.08.003

A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.

PMID: 31221001
Journal: Multiple Sclerosis Journal
Year: 2020
Reference: Mult Scler. 2020 Aug;26(9):1074-1082. doi: 10.1177/1352458519851428. Epub 2019 Jun 21.
Impact factor: 5.412
Publication type: Paper in international publication
Authors: Peroni, Silvia, Sorosina, Melissa, Malhotra, Sunny, Clarelli, Ferdinando, Osiceanu, Ana Maria, Ferre, Laura, Roostaei, Tina, Rio, Jordi, Midaglia, Luciana, Villar, Luisa Maria et al.
DOI: 10.1177/1352458519851428

A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.

PMID: 31221001
Journal: Multiple Sclerosis Journal
Year: 2020
Reference: Mult Scler. 2020 Aug;26(9):1074-1082. doi: 10.1177/1352458519851428. Epub 2019 Jun 21.
Impact factor:
Publication type: Paper in international publication
Authors: Alvarez-Cermeno, Jose Carlos; Citterio, Lorena; Clarelli, Ferdinando; Comabella, Manuel; Comi, Giancarlo; de Jager, Philip; Esposito, Federica; Ferre, Laura; Guaschino, Clara; Lechner-Scott, Jeannette et al.
DOI: 10.1177/1352458519851428

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

PMID: 32410080
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2020
Reference: Invest New Drugs. 2020 Dec;38(6):1774-1783. doi: 10.1007/s10637-020-00928-z. Epub 2020 May 14.
Impact factor: 3.525
Publication type: Paper in international publication
Authors: Kasper, Stefan, Siena, Salvatore, Mesia, Ricard, Berardi, Rossana, Cervantes, Andres, Dekervel, Jeroen, Zhao, Sylvia, Sun, Yongjian, Hao, Huai-Xiang, Tiedt, Ralph et al.
DOI: 10.1007/s10637-020-00928-z

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

PMID: 32410080
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2020
Reference: Invest New Drugs. 2020 Dec;38(6):1774-1783. doi: 10.1007/s10637-020-00928-z. Epub 2020 May 14.
Impact factor:
Publication type: Paper in international publication
Authors: Argiles, Guillem; Berardi, Rossana; Cervantes, Andres; Dekervel, Jeroen; Delord, Jean-Pierre; Fayette, Jerome; Hao, Huai-Xiang; Kasper, Stefan; Mesia, Ricard; Myers, Andrea et al.
DOI: 10.1007/s10637-020-00928-z

A phase 1b/2 study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAF V600E/K-mutant solid tumors.

PMID: 32669376
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Oct 1;26(19):5102-5112. doi: 10.1158/1078-0432.CCR-19-3550. Epub 2020 Jul 15.
Impact factor: 10.107
Publication type: Paper in international publication
Authors: Pickard, Michael, Sandor, Victor, Ascierto, Paolo A, Wollenberg, Lance, Elez, Elena, Lebbe, Celeste, Sullivan, Ryan J, Weber, Jeffrey S, Patel, Sapna P, Dummer, Reinhard et al.
DOI: 10.1158/1078-0432.CCR-19-3550

A phase 1b/2 study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAF V600E/K-mutant solid tumors.

PMID: 32669376
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Oct 1;26(19):5102-5112. doi: 10.1158/1078-0432.CCR-19-3550. Epub 2020 Jul 15.
Impact factor:
Publication type: Paper in international publication
Authors: Ascierto, Paolo A; Carlino, Matteo S; Dummer, Reinhard; Elez, Elena; Lebbe, Celeste; Patel, Sapna P; Pickard, Michael; Sandor, Victor; Siena, Salvatore; Sullivan, Ryan J et al.
DOI: 10.1158/1078-0432.CCR-19-3550

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

PMID: 31776899
Journal: JOURNAL OF NEURO-ONCOLOGY
Year: 2020
Reference: J Neurooncol. 2020 Jan;146(1):79-89. doi: 10.1007/s11060-019-03337-2. Epub 2019 Nov 27.
Impact factor: 3.267
Publication type: Paper in international publication
Authors: van den Bent, Martin, Azaro, Analia, De Vos, Filip, Sepulveda, Juan, Yung, W K Alfred, Wen, Patrick Y, Lassman, Andrew B, Joerger, Markus, Tabatabai, Ghazaleh, Rodon, Jordi et al.
DOI: 10.1007/s11060-019-03337-2

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

PMID: 31776899
Journal: JOURNAL OF NEURO-ONCOLOGY
Year: 2020
Reference: J Neurooncol. 2020 Jan;146(1):79-89. doi: 10.1007/s11060-019-03337-2. Epub 2019 Nov 27.
Impact factor:
Publication type: Paper in international publication
Authors: Azaro, Analia; Balbin, O Alejandro; Cheng, Yi; De Vos, Filip; Joerger, Markus; Kirsilae, Tiina; Lassman, Andrew B; Rodon, Jordi; Sepulveda, Juan; Tabatabai, Ghazaleh et al.
DOI: 10.1007/s11060-019-03337-2

Publications

Publications searcher

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells.

A new standard of care for patients with high-risk rhabdomyosarcoma? - Authors' reply.

A new standard of care for patients with high-risk rhabdomyosarcoma? - Authors' reply.

A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer.

A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer.

A novel autologous-made matrix using hyaline cartilage chips and platelet-rich growth factors for the treatment of full-thickness cartilage or osteochondral defects: Preliminary results.

A novel clinical risk prediction model for myocardial infarction, coronary revascularization, and cardiac death according to clinical, exercise, and gated SPECT variables (VH-RS).

A novel clinical risk prediction model for myocardial infarction, coronary revascularization, and cardiac death according to clinical, exercise, and gated SPECT variables (VH-RS).

A novel id-iri score: development and internal validation of the multivariable community acquired sepsis clinical risk prediction model.

A novel id-iri score: development and internal validation of the multivariable community acquired sepsis clinical risk prediction model.

A parsimonious score with a free web tool for predicting disability after an ischemic stroke: the Parsifal Score.

A parsimonious score with a free web tool for predicting disability after an ischemic stroke: the Parsifal Score.

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.

A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

A phase 1b/2 study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAF V600E/K-mutant solid tumors.

A phase 1b/2 study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAF V600E/K-mutant solid tumors.

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

Patronage:

Collaborating:

Accreditations: